Brief: Ambu Maintains 2023/24 Financial Guidance

Ambu A/S

30/01/2024 07:08

Jan 30 (Reuters) - Ambu A/S  AMBUb.CO :
    * INTERIM REPORT FOR Q1 2023/24
    * IN Q1 2023/24, AMBU DELIVERED 14% ORGANIC REVENUE GROWTH
AND A
10.0% EBIT MARGIN BEFORE SPECIAL ITEMS
    * FY 2023/24 FINANCIAL GUIDANCE STATED ON 8 NOVEMBER 2023 IS
MAINTAINED
    * IMPROVED EBIT MARGIN OF 4.0 %-PTS WAS MAINLY DRIVEN BY
REVENUE
EXPANSION DRIVING SCALE IN OPEX OF 3.6 %-PTS
    * ANAESTHESIA & PATIENT MONITORING WERE AFFECTED BY PRICE
INCREASES IN SELECTED LOW-MARGIN AREAS
    * Q4 ENDOSCOPY SOLUTIONS INCREASED ORGANICALLY BY 25% (3%)
    * GROWTH IN ENDOSCOPY SOLUTIONS WAS  MAINLY DRIVEN BY AMBU’S
PRE-EXISTING SOLUTIONS IN GROWING SINGLE-USE MARKET
    * OUTLOOK 2024: ORGANIC REVENUE GROWTH IS 7-10%
    * OUTLOOK 2024: EBIT MARGIN BEFORE SPECIAL ITEMS IS 8-10%
    * DUE TO LESS IMPACTFUL FLU SEASON, COMPARED TO Q1 LAST 
YEAR,
PULMONOLOGY WAS SIMULTANEOUSLY NEGATIVELY  IMPACTED
    * CONTINUED PROGRESS TO IMPLEMENT BIOPLASTICS IN AMBU'S FULL
FLEET
OF SINGLE-USE ENDOSCOPES BY  EARLY 2024/25

Source text for Eikon:  ID:nGNEhSG5W 
Further company coverage:  AMBUb.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))